| 1 |
Muscedere J. Which antibiotic for hospital acquired pneumonia caused by MRSA?[J]. BMJ, 2014 (348): g1469.
|
| 2 |
Welte T, Pletz MW. Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options[J]. Int J Antimicrob Agents, 2010, 36 (5): 391-400.
|
| 3 |
Ueda T, Takesue Y, Nakajima K, et al. High-dose regimen to achieve novel targettrough concentration in teicoplanin[J]. J Infect Chemother, 2014, 20 (1): 43-47.
|
| 4 |
LeFrock J, Ristuccia A. Teicoplanin in the treatment of bone and joint infections: an open study[J]. J Infect Chemother, 1999, 5 (1): 32-39.
|
| 5 |
Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. JAMA, 2016, 315 (8): 762-774.
|
| 6 |
Matsuo S, Imai E, Horio M. Revised equations for estimated GFR from serum creatinine in Japan[J]. Am J Kidney Dis, 2009, 53 (6): 982-992.
|
| 7 |
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. JAMA, 2016, 315 (8): 801-810.
|
| 8 |
胡萨萨，庞成森，董海燕，等.危重症感染患者血清中替考拉宁浓度测定[J].中国医院药学杂志，2011，31(9):753-755.
|
| 9 |
Hotchkiss RS, Moldawer LL, Opal SM, et al. Sepsis and septic shock[J]. Nat Rev Dis Primers, 2016 (2):16045.
|
| 10 |
Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016[J]. Intensive Care Med, 2017, 43 (3): 304-377.
|
| 11 |
黄颖，寿松涛，王军，等.脓毒症与免疫细胞凋亡相关研究进展[J/CD].中华危重症医学杂志（电子版），2017，10(4):270-273.
|
| 12 |
Sharawy N, Lehmann C. New directions for sepsis and septic shock research[J]. J Surg Res, 2015, 194 (2): 520-527.
|
| 13 |
Cecconi M, Evans L, Levy M, et al. Sepsis and septic shock[J]. Lancet, 2018, 392 (10141): 75-87.
|
| 14 |
Armstrong BA, Betzold RD, May AK. Sepsis and septic shock strategies[J]. Surg Clin North Am, 2017, 97 (6): 1339-1379.
|
| 15 |
Vazquez-Guillamet C, Scolati M, Zilberberg MD, et al. Using the number needed to treat to assess appropriate antimicrobial therapy as a determinant of outcome in severe sepsis and septic shock[J]. Crit Care Med, 2014, 42 (11): 2342-2349.
|
| 16 |
Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program[J]. Crit Care Med, 2014, 42 (8): 1749-1755.
|
| 17 |
张谊芳，石夏莹，蒋杰.替考拉宁临床应用98例合理性分析[J/CD].中华危重症医学杂志（电子版），2014，7(5):361-364.
|
| 18 |
Sato Y, Hiramatsu K, Suzuki Y, et al. Optimal trough concentration of teicoplanin in febrile neutropenic patients with hematological malignancy[J]. Chemotherapy, 2018, 63 (1): 29-34.
|
| 19 |
吕碧君，梁峰华，谢慧，等.替考拉宁在重症肺炎患者中的血药浓度监测与应用分析[J].中国医院药学杂志，2017，37(21):2167-2172,2126.
|
| 20 |
王妍，朱章华，顾勤，等.重症患者不同负荷剂量替考拉宁早期谷浓度的监测[J].中国感染控制杂志，2018，17(2):112-115.
|
| 21 |
Nakano T, Nakamura Y, Takata T, et al. Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis[J]. Int J Clin Pharm, 2016, 38 (4): 908-914.
|